Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The firm focuses on astaxanthin, a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories. Its product platform includes pharmaceutical candidates CDX-101 and CDX-301, and dietary supplement, ZanthoSyn. The company was founded on February 7, 2014 and is headquartered in Honolulu, HI.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company